Tissue transglutaminase (TG-2) modified amniotic membrane : a novel scaffold for biomedical applications by Chau, David Y.S. et al.
Tissue	   transglutaminase	   (TG-­‐2)	   modified	   amniotic	   membrane:	   a	   novel	   scaffold	   for	  
biomedical	  applications	  	  
	  
David	  Y.S.	  Chau1,	  Sheridan	  V.	  Brown1,	  Melissa	  L.	  Mather2,3,	  Victoria	  Hutter4,	  Naing	  L.	  Tint4,5,	  






1Allergy	   Research	   Group,	   School	   of	   Molecular	   Medical	   Sciences,	   Queen’s	   Medical	   Centre,	   The	  
University	  of	  Nottingham,	  Nottingham,	  NG7	  2UH,	  UK	  
 
2Electrical	  Systems	  and	  Optics	  Research	  Division,	  Faculty	  of	  Engineering,	  The	  University	  of	  Nottingham,	  
Nottingham,	  NG7	  2RD,	  UK	  
	  
3Materials	  Division,	  National	  Physical	  Laboratory,	  Teddington,	  Middlesex,	  TW11	  0LW,	  UK	  
	  
4	  Division	  of	  Drug	  Delivery	  and	  Tissue	  Engineering,	  School	  of	  Pharmacy,	  The	  University	  of	  Nottingham,	  
University	  Park,	  Nottingham,	  NG7	  2RD,	  UK	  
	  
5	  Division	  of	  Ophthalmology	  and	  Vision	  Sciences,	  School	  of	  Medicine	  &	  Health	  Sciences,	  The	  University	  of	  








Dr	  Amir	  M.	  Ghaemmaghami	  	  
Associate	  Professor	  in	  Immunology	  
Course	  Director	  for	  MSc	  in	  Immunology	  &	  Allergy	  
School	  of	  Molecular	  Medical	  Sciences	  
A	  Floor,	  West	  Block	  
Queen's	  Medical	  Centre	  






Tel:	  	  +44	  (0)115	  823	  0730	  




Background/Aims:	   The	   amniotic	   membrane	   (AM)	   is	   considered	   as	   a	   natural	   cell	   culture	  
substrate	  and	  has	  occasionally	  been	  exploited	  in	  regenerative	  medicine	  especially	  for	  ocular	  
surface	   reconstruction	   and	   dermal	   wound	   healing	   applications.	   However,	   its	   limited	   use	  
infers	   from	   its	   relatively	   weak	  mechanical	   strength,	   difficulty	   during	  manual	   handling	   and	  
susceptibility	   to	   proteolytic	   degradation	   in	   vivo.	   Therefore,	   in	   this	   study	   we	   aimed	   to	  
enhance	  the	  mechanical	  and	  biological	  characteristics	  of	  the	  AM	  by	  enzymatic	  cross-­‐linking	  it	  
using	  tissue	  transglutaminase	  (TG):	  a	  calcium-­‐dependent	  enzyme	  capable	  of	  forming	  stable	  
ε(γ-­‐glutamyl)lysine	   cross-­‐linkages.	   Using	   a	   biological	   catalyst	   such	   as	   TG	   should	   not	   only	  
prevent	  denaturation	  during	  sample	  preparation	  but	  also	  minimise	  the	  potential	  of	  residual	  
chemical	  cross-­‐linking	  agents	  compared	  to	  alternative	  methodologies.	  	  
	  
Methods:	  Human	  AM,	   sourced	   from	   elective	   caesarean	   sectioning,	  were	   treated	  with	   TG,	  
BSA	  and/or	  a	  no-­‐treatment	  control.	  Samples	  were	  then	  compared	  in	  terms	  of	  their	  physical	  
characteristics	   (SEM,	   transparency,	   mechanical	   strength,	   susceptibility	   to	   proteolytic	  
degradation),	  biological	  characteristics	  (in	  vitro	  cell	  culture,	  activation	  of	  dendritic	  cells)	  and	  
its	   in	   vivo	   biocompatibility/angiogenic	   capacity	   (chick	   chorioallantoic	   membrane	   (CAM)	  
assay).	  	  
	  
Results:	  Transglutaminase-­‐treated	  AM	  exhibited	  enhanced	  mechanical	  strength	  and	  greater	  
resistance	  to	  proteolytic/collagenase	  degradation	  compared	  to	  the	  control(s).	  SEM	  imaging	  
of	   the	   TG-­‐treated	   membrane	   summarised	   a	   significantly	   closer	   association	   and	   greater	  
interconnectivity	  of	  individual	  collagen	  fibres	  yet	  it	  had	  no	  effect	  on	  the	  overall	  transparency	  
of	  the	  AM.	   In	  vitro	  cell	  culture	  demonstrated	  no	  detrimental	  effect	  of	  TG-­‐treatment	  on	  the	  
AM	   in	   terms	  of	   cell	   attachment,	   spreading,	  proliferation	  and	  differentiation.	  Moreover,	   an	  
“immune	   response”	   was	   not	   elicited	   based	   on	   extended	   in	   vitro	   culture	   with	   human	  
monocyte-­‐derived	   dendritic	   cells	   (mDC).	   Interestingly,	   the	   TG-­‐treated	   AM	   still	   allowed	  
angiogenesis	   to	  occur	  and	   in	  some	   instances,	  demonstrated	  an	  enhancement	  compared	  to	  
the	  control	  (n	  =	  5).	  	  
	  
Conclusion:	  We	   hereby	   demonstrate	   that	   treating	   the	   AM	  with	   the	   cross-­‐linking	   enzyme,	  
transglutaminase,	   results	   in	   a	   novel	   biomaterial	   with	   enhanced	  mechanical	   and	   biological	  
characteristics.	   Above	   all,	   this	   modified	   membrane	   demonstrates	   greater	   strength,	  
maintains	  in	  vitro	  cell	  growth,	  retains	  optical	  transparency	  and	  allows	  angiogenesis	  to	  occur	  
without	   inducing	   an	   immune	   response.	   Taken	   together,	   this	   study	   demonstrates	   the	  
feasibility	  of	  transglutaminase	  as	  an	  alternate	  cross-­‐linking	  treatment	  for	  the	  production	  of	  
novel	  biomaterials	  and	  suggests	  that	  TG-­‐treated	  AM	  may	  now	  be	  more	  commonly	  exploited	  
as	  a	  therapeutic	  dressing	  for	  ocular	  or	  wound	  applications.	  	  	  
	  
	  
Keywords:	   amniotic	   membrane,	   biomaterials,	   cross-­‐linking,	   tissue	   engineering,	  
transglutaminase	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1.	  INTRODUCTION	  	  
The	  human	  amniotic	  membrane	  (AM)	  which	  represents	  the	  innermost	  layer	  of	  the	  placenta	  
is	   composed	   of	   three	   distinct	   strata,	   namely	   a	   single	   epithelial	   layer,	   the	   thick	   basement	  
membrane	  and	  an	  avascular	  stroma	  [Sippel	  et	  al.,	  2001].	  Moreover,	  there	   is	  an	  absence	  of	  
nerves,	   muscles	   and	   lymphatics	   from	   the	   AM	   structure	   [Toda	   et	   al.,	   2007].	   The	   clinical	  
potential	   of	   the	   AM	   was	   first	   considered	   over	   100	   years	   ago	   by	   JW	   Davis	   as	   a	   surgical	  
material	   in	   skin	   transplantation	   [Davis,	   1910].	   Since	   then,	   the	   exploitation	   of	   the	   AM	   has	  
rapidly	   expanded	   and	   is	   now	   utilised	   in	   a	   variety	   of	   applications	   which	   include	   biological	  
dressings	   (e.g.	   for	  wounds,	   ulcers,	   burns),	   as	   a	   tissue	   substitute	   for	   reconstructive	   surgery	  
and	  as	  a	  novel	  cell	  culture	  scaffold	  material	  for	  tissue	  engineering	  and	  regenerative	  medicine	  
applications	   [reviewed	   by	   Parolini	   et	   al.,	   2009;	   Niknejad	   et	   al.,	   2008;	   Lineen	   and	   Namias,	  
2008;	  Toda	  et	  al.,	  2007;	  Hodde,	  2002].	  However,	  by	  far	  the	  most	  common	  usage	  of	  the	  AM	  
has	   been	   in	   the	   field	   of	   ophthalmology	   as	   a	   treatment	   for	   a	   variety	   of	   ocular	   surface	  
disorders.	   The	   AM	   itself	   possesses	   several	   key	   characteristics	   which	  make	   it	   desirable	   for	  
medical	   and/or	   therapeutic	   applications	   and	   include	   its	   ease	   of	   sourcing,	   good	  
biocompatibility,	  low	  immunological	  response,	  natural	  antimicrobial	  properties,	  anti-­‐scarring	  
and	   anti-­‐fibrotic	   effects	   and	   also,	   being	   capable	   of	   inducing	   enhanced	   cell	   and	   cellular	  
characteristics	   [Niknejad	   et	   al.,	   2008;	   Dua	   et	   al.,	   2004;	   Dua	   and	   Azuara-­‐Blanco,	   1999].	  
However,	   the	   limitations	   for	   further	   exploitation	   of	   the	   AM	   reside	   in	   its	   innate	   weak	  
mechanical	   characteristics,	   susceptibility	   to	   proteolytic	   degradation	   and	   stability	   following	  
long-­‐term	  storage.	  Moreover,	   the	  membrane	   is	   frequently	  prone	   to	   crumbling/folding	  and	  
requires	  trained	  and	  skilled	  manual	  handling	  to	  adequately	  exploit	  successfully.	  	  
	  
The	   major	   components	   that	   contribute	   to	   the	   AM	   matrix	   structure	   include	   a	   variety	   of	  
collagens,	   proteoglycans	   and	   non-­‐collagenous	   glycoproteins	   (i.e.	   fibronectin	   and	   laminin)	  
[Sippel	   et	   al.,	   2001;	   Campbell	   et	   al.,	   1989;	   Yurchenco	   and	   Ruben,	   1987].	   As	   such,	   several	  
methods	  (derived	  from	  established	  methodologies	  involved	  in	  the	  cross-­‐linking	  of	  collagens)	  
have	  been	  employed	  to	  cross-­‐link	  AM	  to	  improve	  its	  mechanical	  properties	  and	  prevent	  its	  
rapid	  absorption	  by	  the	  body	  [Lee	  et	  al.,	  2001;	  Fujisato	  et	  al.,	  1999].	  However,	  the	  majority	  
of	  these	  methods	  are	  susceptible	  to	  leaving	  residual	  catalysts	  and/or	  by-­‐products	  that	  may	  
be	  toxic	  or	  cause	  an	  inflammatory	  response	  or,	  simply,	  not	  practical	  or	  cost	  effective	  at	  the	  
large-­‐scale	   [Matuda	   et	   al.,	   1999;	   Ben-­‐Slimane	   et	   al.,	   1988;	   Dunn	   et	   al.,	   1969].	  Moreover,	  
radiation	   treatment	  with	  γ-­‐ray	  and	  electron	  beams	  demonstrated	  a	   significant	  decrease	   in	  
both	  the	  tensile	  strength	  and	  elongation	  at	  break	  characteristics	  of	  the	  AM	  [Fujisato	  et	  al.,	  
1999]	   as	   well	   as	   collagen	   derived	   from	   native	   AM	   [Liu	   et	   al.,	   1989].	   As	   such,	   alternative	  
methods	   are	   sought	   to	   enhance	   the	   physical	   characteristics	   of	   biological	  membranes	   in	   a	  
more	   natural,	   efficient	   and	   practical	  manner	   but,	  most	   importantly,	   without	   inducing	   any	  
detrimental	  effects	  on	  both	  the	  sample	  and/or	  patient.	  	  
	  
Transglutaminase	   (EC	  2.3.2.13)	  are	  a	  group	  of	  ubiquitously	  distributed	  enzymes	  capable	  of	  
catalysing	   the	   linkage	   of	   peptides	   or	   proteins	   together	   to	   form	   multimers,	   via	   an	   ε(γ-­‐
glutamyl)lysine	  cross-­‐link,	  using	  the	  side	  chains	  of	   lysine	  and	  	  glutamine	  residues	  [Griffin	  et	  
al.,	  2002].	  Moreover,	  transglutaminases	  (TG)	  are	  also	  able	  to	  covalently	  bind	  primary	  amine	  
containing	  compounds	  to	  peptide	  bound	  glutamine	  facilitating	  the	  modification	  of	  proteins	  
[Griffin	  et	  al.,	  2002].	  As	  such,	  these	  enzymes	  have	  frequently	  been	  exploited	  in	  a	  wide	  range	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of	  commercial	  applications	  including	  the	  modification	  of	  food,	  textiles	  and	  cosmetics	  [Cortez	  
et	   al.,	   2002;	   Kuraishi	   et	   al.,	   1997;	   Bailey	   et	   al.,	   1996;	   Rasmussen	   et	   al.,	   1996;	   Ishii	   et	   al.,	  
1994].	   However,	   the	   greatest	   potential	   by	   far	   has	   been	   the	   enzymes’	   exploitation	   in	  
therapeutic	   and	   regenerative	   medical	   applications	   due	   to	   its	   ability	   to	   enhance	   both	   the	  
mechanical	   and	   biological	   characteristics	   of	   key	   biological	   substrates.	   As	   such,	   novel	  
biomaterials	   and	   biological	   substitutes	   derived	   from	   several	   biological	   molecules	   (e.g.	  
collagen,	   fibrin,	   gelatin	   and	   chitosan)	   have	   been	   developed	   over	   the	   years	   and	   currently	  
pursuing	  a	  pathway	  towards	  clinical	  and	  therapeutic	  potential	  [Lorentz	  et	  al.,	  2010;	  Collighan	  
and	  Griffin,	  2009;	  Yung	  et	  al.,	  2007;	  Chau	  et	  al.,	  2005;	  Broderick	  et	  al.,	  2005;	  McDermott	  et	  
al.,	  2004;	  Orban	  et	  al.,	  2004;	  Ito	  et	  al.,	  2003;	  Greenberg	  et	  al.,	  1991].	  	  
	  
In	  this	  study,	  we	  aim	  to	  demonstrate	  the	  efficacy	  and	  effect	  of	  treating	  the	  AM	  with	  TG	  and	  
evaluating	   the	   resultant	   mechanical	   and	   biological	   properties	   of	   the	   modified	   membrane	  


































2.	  MATERIALS	  AND	  METHODS	  	  
All	  chemicals	  were	  purchased	  from	  Sigma	  Aldrich	  (Poole,	  UK)	  unless	  otherwise	  stated.	  Sterile	  
preparation	  of	  stock	  solutions	  and	  chemicals	  were	  performed	  either	  by	  filtration	  through	  a	  
0.22µm	   Whatmann	   sterile	   filter	   and/or	   autoclaving	   at	   121°C	   at	   1bar	   for	   45	   minutes.	  
Handling	  and	  disposal	  of	  the	  AM	  was	  performed	  in	  accordance	  with	  local	  human	  biological	  
regulations	  and	  all	  AM	  manipulation	  performed	  under	  a	  sterile	  environment,	  using	  aseptic	  




Human	   AM	   were	   collected	   from	   mothers	   undergoing	   elective	   caesarean	   sectioning	   and	  
obtained	   with	   prior	   written	   consent	   and	   the	   approval	   of	   the	   University	   of	   Nottingham	  
Medical	   School/Nottingham	   Research	   Ethics	   Committee.	  Membranes	   were	   obtained	   from	  
patients	  who	  delivered	  healthy,	  near-­‐term	  children	  with	  no	  gestational	  issues	  and	  the	  entire	  
study	  performed	  under	  the	  principles	  of	  the	  Declaration	  of	  Helsinki.	  
	  
	  
Amniotic	  membrane	  preparation,	  processing	  and	  treatment	  
Amniotic	  membranes	  were	   prepared	   in	   accordance	  with	   a	   previously	   established	   protocol	  
[Hopkinson	  et	  al.,	  2006].	  Briefly,	  the	  chorion	  was	  manually	  separated	  from	  the	  amnion	  and	  
discarded	  before	  the	  remaining	  membrane	  treated	  with	  0.5%	  levofloxacin	  in	  PBS	  to	  remove	  
residual	  blood.	  Persistent	  blood-­‐stained	  AM	  edges	  were	  removed	  by	  dissection.	  AM	  samples	  
were	   acquired	   from	   the	   uniform	   and	   translucent	   areas	   adjacent	   to	   the	   placental	   disc	  
(proximal	  amnion)	  and	  placental	  disc	  (distal	  amnion)	  before	  being	  placed	  at	  -­‐80°C	  in	  PBS	  for	  
long-­‐term	  storage	  and	  to	  ensure	  no	  transmission	  of	  diseases	  to	  occur	  (>	  6	  months).	  	  
	  
Prior	  to	  immediate	  use	  and	  under	  a	  sterile	  environment,	  AM	  samples	  were	  thawed	  at	  37°C	  
before	   being	   washed	   twice	   with	   fresh	   PBS	   and	   then	   cut	   into	   squares	   with	   dimensions	  
approximately	  1cm	  x	  1cm.	  Triplicate	   samples	  were	  acquired	   from	   the	   same	   locality	  where	  
possible	   and	   then	   incubated,	   24h,	   with	   1%	   (w/v)	   tissue	   transglutaminase	   (TG;	   guinea	   pig	  
liver)	  in	  reaction	  buffer	  (2mM	  CaCl2,	  1mM	  DTT	  in	  PBS),	  1%	  (w/v)	  bovine	  serum	  albumin	  (BSA)	  
in	  PBS	  and	  PBS	  only	   (untreated	  control)	   in	  a	  humidified-­‐atmosphere	   incubator	  at	  37°C	  and	  
with	   5%	   CO2.	   Samples	   were	   kept	   on	   rocking	   platform	   (Stuart	   Gryo-­‐Rocker	   SSL3,	   default	  
settings:	  21)	   throughout	   the	   incubation	   step.	   Following	   treatment,	  AM	  were	   removed	  and	  
washed	  once	  with	  2mM	  EDTA	   in	  PBS	  and	  then	  once	  more	  with	  PBS	  solution	  only.	  Samples	  
were	  then	  used	  immediately	  where	  possible	  or	  stored	  at	  4°C,	  in	  PBS,	  and	  used	  within	  5	  days	  
following	   initial	   treatment.	   In	   all	   experiments,	   the	   following	   controls	  were	   included	   in	   the	  
set-­‐up	   and	   used	   for	   comparative	   studies.	   Inactivated	   TG	   (TG	   pre-­‐treated	  with	   2mM	   EDTA	  
and	  without	   the	   addition	   of	   CaCl2),	   BSA-­‐treatment	   as	   a	   protein	   control	   and	   tissue	   culture	  






Transglutaminase	  activity	  assay	  
Transglutaminase	  cross-­‐linking	  activity	  was	  determined	  using	  a	   slightly	  modified	  version	  of	  
the	  hydroxamate	  assay	  developed	  by	  Folk	  and	  Chung	  [Folk	  and	  Chung,	  1985].	  Briefly,	  25µl	  of	  
TG	  sample	  was	  mixed	  with	  75µl	  of	  Reagent	  A	  (0.2M	  sodium	  acetate	  (pH	  6.0),	  0.03M	  CBZ-­‐Gln-­‐
Gly,	  0.1M	  hydroxylamine,	  0.01M	  glutathione,	  5mM	  CaCl2,	  5mM	  DTT)	   in	  a	  well	  of	  a	  96-­‐well	  
plate.	  Following	  incubation	  at	  37°C	  for	  10	  minutes,	  75µl	  of	  Reagent	  B	  (1	  volume	  of	  3N	  HCl,	  1	  
volume	  12%	  trichloroacetic	  acid,	  1	  volume	  5%	  FeCl3.6H2O	  (dissolved	  in	  0.1N	  HCl))	  was	  added	  
to	  the	  well	   in	  order	  to	  terminate	  the	  reaction	  by	  the	  co-­‐formation	  of	  an	   iron	  complex.	  The	  
resultant	   absorbance	   was	   read	   at	   492nm	   using	   an	   Optima	   FLUOstar®plate	   reader	   (BMG	  
LabTech,	   Aylesbury,	   UK).	   A	   unit	   of	   transglutaminase	   activity	   is	   defined	   as	   the	   amount	   of	  
enzyme	   catalysing	   the	   formation	   of	   1µmol	   of	   hydroxamic	   acid	   per	   minute	   under	   the	  
described	  reaction	  conditions.	  	  
	  
	  
Scanning	  electron	  microscopy	  (SEM)	  
Macro-­‐	  and	  micro-­‐scope	  assessment	  of	  the	  AM	  samples	  was	  performed	  using	  SEM.	  Briefly,	  
untreated	   and	   treated	   AM	   samples	  were	   fixed	   24h	  with	   3%	   (v/v)	   glutaraldehyde,	  washed	  
with	   PBS	   before	   being	   treated	   with	   1%	   (v/v)	   osmium	   tetraoxide	   solution	   for	   2	   hours.	  
Following	   this	   fixation	  step,	   samples	  were	  washed	  with	  distilled	  water	  and	   then	  processed	  
through	   a	   series	   of	   10	  minute	   dehydration	   steps	   involving	   ethanol	   (25%,	   50%,	   70%,	   90%,	  
95%	  and	  100%)	  before	  being	  left	  to	  air-­‐dry	  at	  room	  temperature	  (19°C).	  Samples	  were	  then	  
mounted	  on	  aluminium	  SEM	  stubs	  using	  double-­‐sided	  carbon	  tape	  and	  then	  gold	  coated,	  for	  
3	  min,	   under	   an	   argon	   atmosphere.	   Coated	   samples	   were	   examined	   using	   a	   variable	  
pressure	  JOEL	  6060LV	  unit	  operating	  at	  an	  accelerating	  voltage	  of	  10	  kV.	  Image	  analysis	  was	  
carried	  out	  using	  the	  in-­‐built	  SEM	  Control	  User	  Interface	  software	  (version	  6.57)	  and	  digital	  
imaging	  system.	  	  
	  
	  
Mechanical	  testing	  and	  characterisation	  (Love	  wave)	  
	  
The	  mechanical	  strength	  of	  the	  untreated	  and	  treated	  AM	  was	  assessed	  using	  a	  Love	  wave	  
surface	   acoustic	   device	   (donated	   by	   CSIRO	   Materials	   Science	   and	   Engineering,	   Australia).	  
Love	   wave	   devices	   are	   layered	   structures	   consisting	   of	   a	   piezoelectric	   substrate	   and	   a	  
guiding	  layer	  which	  couples	  the	  acoustic	  wave	  to	  the	  near	  surface.	  Typically	  two	  inter-­‐digital	  
transducers,	  separated	  by	  a	  propagation	  path,	  are	  embedded	  at	  the	  interface	  between	  the	  
substrate	  and	  guiding	  layer.	  These	  transducers	  are	  used	  to	  transmit	  and	  receive	  the	  acoustic	  
waves	   in	  a	  delay	   line	  configuration	   (see	   figure:	   caption	   for	   figure:	  Schematic	  of	   Love	  wave	  
device	   consisting	   of	   a	   piezoelectric	   substrate,	   guiding	   layer	   and	   interdigital	   transducers.	   A	  
test	   sample	   is	   shown	   along	   the	   propagation	   path).	   The	   loading	   of	   a	   sample	   along	   the	  
propagation	   path	   of	   the	   device	   induces	   damping	   in	   the	   wave	   (Δα)	   and	   a	   change	   in	   the	  
wavenumber	  (Δβ)	  [G	  Kovacs,	  MJ	  Vellekoop,	  R	  Haueis,	  GW	  Lubking,	  A	  Venema,	  “A	  Love	  wave	  
sensor	  for	  (bio)chemical	  sensing	  in	  liquids,	  Sensors	  and	  Actuators	  A,	  43	  1994	  p38-­‐43”].	  These	  
changes	   can	   be	   studied	   using	   perturbation	   theory	   and	   expressed	   in	   terms	  of	   the	   complex	  
shear	  modulus	  (G*)	  as	  follows:	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𝑮∗ = 𝟏𝑺𝟐𝝆 ∆𝜶𝜷 𝟐 − ∆𝜷𝜷 𝟐 + 𝟐𝒊 𝟏𝑺𝟐𝝆 ∆𝜶𝜷 ∆𝜷𝜷 	   	   	   	   	   	   (1)	  
	  
where	   S	   is	   the	   device	   sensitivity	   and	   ρ	   is	   the	   sample	   density	   and	   β	   is	   the	   unperturbed	  
wavenumber	   [V	   Raimbault,	   D	   Rebiere,	   C	   Dejous,	   M	   Guirardel,	   J	   Pistre,	   JL	   Lachaud,	   High	  
frequency	  microrheological	  measurements	   of	   PDMS	   fluids	   using	   SAW	  microfluidic	   system,	  
Sensors	  and	  Actuators	  B,	  144,	  2010,	  p467-­‐471].	  The	  real	  part	  of	  the	  complex	  shear	  modulus	  
can	  be	  used	  to	  assess	  the	  mechanical	  strength	  of	  the	  loaded	  sample.	  
	  
In	   the	   current	   work	   the	   Love	   wave	   device	   consisted	   of	   two	   inter-­‐digital	   piezoelectric	  
transducers	  (6mm	  separation	  path	   length)	  on	  a	  ST-­‐cut	  quartz	  substrate	  which	  were	  coated	  
with	  a	  guiding	  layer	  of	  silicon	  dioxide	  and	  operated	  at	  a	  frequency	  of	  118MHz.	  A	  control	  unit	  
provided	  power	  to	  the	  device	  and	  an	  oscilloscope	  was	  used	  to	  detect	  the	  received	  signals;	  a	  
background	  signal	  reading	  was	   initially	  obtained	  using	  an	  unloaded	  device	  before	  a	  sample	  
of	  the	  membrane	  (0.3cm	  x	  0.3cm)	  was	   loaded	  and	  the	  resultant	  signal	  determined.	  Signals	  
were	   digitised	   and	   analysed	   using	   Matlab	   (The	   Mathworks,	   Cambridge,	   UK)	   before	   the	  
mechanical	   strength	   of	   the	  membranes	   assessed	   using	   Equation	   1.	   For	   the	   corresponding	  
calculations,	  the	  density	  of	  the	  hydrated	  AM	  was	  taken	  to	  be	  the	  same	  as	  water	  (997.6Kg/m3	  
at	  23°C).	  	  
	  
Transparency	  assay	  
The	   optical	   characteristics	   of	   the	   AM	   were	   assessed	   using	   a	   simple	   modification	   of	   the	  
transparency	  assay	  as	  previously	  described	  by	  Ma	  and	  colleagues	  [Ma	  et	  al.,	  2010].	  Briefly,	  
membranes	   were	   placed	   over	   a	   sample	   of	   waterproof	   text	   card	   and	   the	   resulting	   image	  
captured	  using	  a	  Fujitsu	  F80EXR	  12MP	  digital	  camera.	  
	  
	  
Proteolytic	  degradation	  of	  AM	  (using	  collagenase)	  
The	   susceptibility	   to	   proteolytic	   degradation	   of	   the	   untreated	   and	   treated	   AM	   substrates	  
was	   assessed	   using	   a	   controlled	   digestive	   assay	   involving	   microbial	   collagenase	   (C.	  
histolyticum,	   Type	   IA,	   0.5-­‐5.0	  FALGPA	   units/mg	   solid).	   In	   short,	   AM	   samples	  were	  washed	  
twice	   with	   PBS,	   a	   single	   wash	   with	   distilled	   water	   and	   then	   incubated	   with	   a	   1mg/ml,	  
0.2mg/ml	   or	   0.002mg/ml	   collagenase	   solution.	   Samples	   were	   kept	   in	   a	   humidified-­‐
atmosphere	   incubator	   at	   37oC	   and	   with	   5%	   CO2	   for	   selected	   time-­‐points	   before	   being	  
washed	   twice	   with	   PBS.	   Samples	   were	   then	   viewed	   using	   a	   Veho	   VMS-­‐004	   Discovery	  
microscope	   and	   images	   captured	   using	   the	   in-­‐built	   camera	   and	   Q-­‐Capture	   software.	   In	  
addition,	   supernatants	  were	  also	  collected	   from	  each	  of	   the	   individual	  membrane	  samples	  
and	   the	   protein	   concentration	   quantified	   using	   the	   Bio-­‐Rad	  DC	   protein	   assay	   kit	   (Bio-­‐Rad,	  
Hemel	  Hempstead,	  UK)	  according	  to	  the	  manufacturer’s	  instructions	  before	  the	  absorbance	  
was	  read	  at	  750nm	  using	  a	  Tecan	  Infinite®	  M200	  PRO	  plate	  reader	  (Tecan,	  Reading,	  UK).	  
	  
	  
Cell	  culture	  and	  AM-­‐cell	  preparation	  	  	  
The	  human	  epithelial	  cell	  line,	  U5637,	  derived	  from	  a	  grade	  II	  urinary	  bladder	  carcinoma	  was	  
used	   during	   its	   low	   (3-­‐10)	   passage	   numbers	   (LGC	   Standards,	   Middlesex,	   UK).	   These	   cells	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were	   cultured	   and	   maintained	   as	   an	   adherent	   monolayer	   in	   T-­‐flasks	   in	   complete	   media	  
(RPMI	   1640	   supplemented	   with	   10%	   (v/v)	   FBS,	   2mM	   L-­‐glutamine	   and	   1%	   (v/v)	   penicillin-­‐
streptomycin).	  Flasks	  were	  kept	  in	  a	  humidified-­‐atmosphere	  incubator	  at	  37oC	  and	  with	  5%	  
CO2.	   Cells	   were	   routinely	   passaged	   to	   ensure	   that	   they	   were	   between	   50%	   and	   90%	  
confluency	  at	  all	   times.	  For	  detachment,	  a	  standard	   trypsinisation	  protocol	  was	  performed	  
using	  0.25%	  (w/v)	  trypsin/2mM	  EDTA	  in	  PBS.	  	  
	  
Dendritic	  cells	  (DC)	  were	  generated	  from	  peripheral	  blood	  monocytes	  of	  healthy	  volunteers	  
as	   previously	   described	   [Horlock	   et	   al.,	   2007].	   Briefly,	   PBMC	   were	   separated	   from	  
heparinised	   whole	   blood	   by	   a	   standard	   density	   gradient	   centrifugation	   protocol	   using	  
Histopaque®1077	   (Sigma,	  Poole,	  UK).	  Monocytes	  were	  purified	  using	   the	  MACS™	  anti-­‐CD14	  
microbeads	  separation	  kit	  (Miltenyi	  Biotec,	  Woking,	  UK)	  and	  the	  recovered	  cells	  cultured	  in	  
RPMI	  medium	  supplemented	  with	  10%	  (v/v)	  FCS,	  2mM	  L-­‐glutamine	  and	  1%	  (v/v)	  penicillin-­‐
streptomycin	  solution,	  250U/ml	  recombinant	  human	  (rh)	  IL-­‐4	  and	  50ng/ml	  rhGM-­‐CSF	  (R&D	  
Systems,	  Oxford,	  UK)	   to	  promote	  differentiation	   to	  DC.	  As	  such,	  cells	  obtained	  using	   these	  
methodologies	   are	   termed	   monocyte-­‐derived	   dendritic	   cells	   (mDC)	   hereinafter.	   mDC	  
phenotype	  was	  assessed	  using	   flow	  cytomtetry	   for	  a	   selection	  of	   cell	   surface	  markers	   (see	  
below)	  and	  demonstrated	  typical	  phenotype	  of	  immature	  DC	  (Horlock	  et	  al.,	  2007).	  PBS	  pre-­‐
wetted	  0.5cm2	  AM	  squares	  were	  placed	   flat	   into	   the	  wells	  of	   a	  24-­‐well	  plate	  before	  being	  
seeded	  with	  100µl	  of	   the	  appropriate	  cells	  at	  a	   concentration	  of	  8.35x106	  cells/ml	   (U5637)	  
and	   6.03x105	   cells/ml	   (DC).	   Plates	   were	   then	   incubated	   for	   20	   minutes	   in	   a	   humidified-­‐
environment,	  at	  37oC	  and	  with	  5%	  CO2,	  before	  an	  additional	  200µl	  of	  complete	  media	  was	  
added	  to	  each	  sample.	  	  
	  
	  
Cell	  viability	  and	  proliferation	  	  
Cell	   viability	   was	   assessed	   using	   the	   CellTiter	   AQ	   One	   Solution	   Cell	   Proliferation™	   (MTS)	  
assay	  kit	  (Promega,	  Southampton,	  UK)	  according	  to	  the	  Manufacturer's	  instructions.	  Briefly,	  
assays	   were	   performed	   under	   reduced	   lighting	   by	   the	   addition	   of	   20µl	   of	   CellTiter	   AQ	  
reagent	  into	  the	  relevant	  samples	  containing	  100µl	  of	  culture	  medium	  (or	  variations	  thereof	  
using	   a	   1:5	   ratio	   of	   the	   AQ	   reagent:culture	   media).	   Samples	   were	   then	   incubated	   in	   a	  
humidified-­‐atmosphere	   incubator	   at	   37°C	   and	   with	   5%	   CO2	   for	   60	   minutes	   before	   the	  




Cell	  attachment	  and	  spreading	  	  
At	   specified	   time-­‐points	   following	   initial	   cell	   seeding,	   samples	  were	  washed	  once	  with	  PBS	  
before	  being	  fixed	  in	  4%	  (w/v)	  paraformaldehyde	  for	  20	  minutes.	  Samples	  were	  then	  washed	  
twice	  with	  PBS,	  permeabilised	  by	  the	  addition	  of	  0.1%	  (v/v)	  Triton	  X-­‐100	  in	  PBS	  (15	  minutes),	  
washed	   twice	  again	  with	  PBS	  and	   then	   stained	  using	  a	  dual	   staining	  protocol	   consisting	  of	  
May-­‐Grunwald	  stain	  (0.25%	  (w/v)	  in	  methanol)	  (15	  minutes),	  wash	  in	  PBS,	  and	  Giemsa	  stain	  
(0.4%	   (w/v)	   in	  methanol,	   diluted	   1:50	   with	   water)	   (20	  minutes).	   A	   final	   two	   washes	   with	  
distilled	  water	  were	  performed	  before	  samples	  were	  left	  to	  air-­‐dry	  (room	  temperature)	  and	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imaged	  through	  a	  Nikon	  SM21500	  microscope	  and	  images	  captured	  using	  the	  in-­‐built	  Nikon	  
Digital	  DS-­‐L1	  image	  capture	  unit.	  Pictures	  were	  analysed	  using	  Scion	  Image™	  software	  (Scion	  
Corporation,	  Maryland,	  USA).	  Spread	  cells	  were	  distinguished	  and	  characterised	  based	  upon	  
the	  presence	  of	  a	  clear	  halo	  of	  cytoplasm	  surrounding	  their	  nucleus	  as	  previously	  described	  
by	  Jones	  and	  colleagues	  [Jones	  et	  al.,	  1997].	  
	  
	  
Flow	  cytometry	  (expression	  of	  cell	  surface	  markers)	  	  
Expression	   of	   cell	   surface	   markers	   on	   mDC	   was	   assessed	   by	   the	   addition	   of	   monoclonal	  
antibodies,	  conjugated	  to	   the	   fluorophores,	  FITC,	  PE	  or	  PCy5,	  with	  specificity	   for	   individual	  
cell	   surface	   markers.	   All	   antibodies	   and	   isotype	   controls	   were	   purchased	   from	   Beckman	  
Coulter	   (High	  Wycombe,	  UK)	  unless	  otherwise	   stated.	  The	  panel	  of	  antibodies	  used	   in	   this	  
investigation	   include:	   PE-­‐CD11c	   (clone	   BU15,	   IgG1),	   FITC-­‐CD54	   (clone	   84H10,	   IgG1),	   PCy5-­‐
CD83	   (clone	  HB15a,	   IgG2b),	  PE-­‐CD86	   (clone	  HA5.2B7,	   IgG2bκ),	  PE-­‐CD206	   (clone	  3.29B1.10,	  
IgG1),	   PE-­‐CD209	   (clone	  AZND1,	   IgG1)	   and	  PCy5-­‐HLA-­‐DR	   (Immu-­‐357,	   IgG1).	  Additionally,	   an	  
unstained	  sample	  and	  the	  appropriate	  isotype	  controls	  were	  included	  in	  each	  batch	  analysis	  
to	   address	   autofluorescence	   and	   non-­‐specific	   binding,	   respectively.	   Surface	   staining	   was	  
performed	   as	   previously	   described	   [Royer	   et	   al.,	   2010].	   Cells	  were	   harvested	   and	  washed	  
twice	  with	  PBA	  (0.5%	  (w/v)	  BSA	  and	  0.1%	  (w/v)	  sodium	  azide	  in	  PBS).	  In	  the	  final	  wash,	  the	  
supernatant	  was	  removed	  and	  5µl	  of	  each	  of	   the	  antibodies	  of	   interest	  were	  added	  to	  the	  
resultant	  cell	  pellet	  before	  being	  vortexed	  and	  incubated,	  in	  the	  dark,	  for	  20	  minutes	  at	  4°C.	  
Samples	  were	   then	  washed	  with	  PBA	  before	   the	  addition	  of	  600µl	  of	   fixing	   solution	   (0.5%	  
(v/v)	  formaldehyde,	  in	  PBS)	  and	  then	  stored	  in	  the	  dark,	  at	  4°C,	  until	  acquisition	  using	  a	  flow	  
cytometer.	   A	  maximum	   of	   7	   days	   was	   allowed	   for	   the	   storage	   of	   the	   fixed	   samples	   prior	  
analysis.	   Data	   for	   each	   cell	   surface	   marker	   was	   acquired	   using	   a	   Beckman	   Coulter	   EPICS	  
Altra™	  flow	  cytometer	  (Beckman	  Coulter,	  High	  Wycombe,	  UK).	  Each	  sample	  population	  was	  
gated	   to	   only	   include	   cells	   of	   interest	   based	   on	   their	   forward	   scatter	   (cell	   size)	   and	   side	  
scatter	   (cell	   granularity)	   profiles	   and	   on	   the	   basis	   of	   the	   expression	   of	   certain	   cell	   surface	  
markers	  (i.e.	  CD11c	  and/or	  HLA-­‐DR	  for	  DC	  lineage).	  A	  total	  of	  8000	  events	  were	  collected	  for	  
each	   sample.	   Raw	   data	   were	   analysed	   using	   WinMDI	   2.9	   software	   (build	   #2,	   6-­‐19-­‐2000;	  
Scripps	   Research	   Institute.	   http://facs.scripps.edu/software.html)	   and	   the	   absolute	   mean	  
fluorescence	   intensity	   (MFI)	   value	   for	   each	  marker	  was	  determined.	  Absolute	  MFI	   value	   is	  
defined	  as:	  [absolute	  MFI]	  =	  [MFI	  value	  of	  sample]	  –	  [MFI	  value	  of	  isotype/unstained	  sample]	  
	  
	  
Endocytosis	  of	  DC	  
Assessment	   of	   endocytosis	   was	   performed	   by	   measuring	   the	   uptake	   of	   FITC-­‐dextran	   as	  
previously	  described	  [Garcia-­‐Nieto	  et	  al.,	  2010].	  mDC	  were	  collected	  and	  washed	  with	  cold	  
PBS	   (4°C)	   before	   being	   resuspended	   in	   cold	   serum-­‐free	   RPMI	  medium	   (4°C)	   and	   split	   into	  
four	   eppendorfs	   (i.e.	   ~5	   x	   105	   cells/ml	   in	   500µl	   per	   eppendorf)	   per	   sample.	   FITC-­‐dextran	  
(Sigma,	   Poole,	   UK)	   was	   then	   added,	   at	   a	   final	   concentration	   of	   1mg/ml,	   to	   two	   of	   the	  
eppendorfs	   while	   the	   remaining	   two	   were	   left	   unstained.	   One	   each	   of	   the	   stained	   and	  
unstained	  samples	  were	  then	  placed	   into	  a	  humidified	   incubator	   (37°C	  and	  5%	  CO2)	   for	  90	  
minutes.	  The	  remaining	  stained	  and	  unstained	  samples	  were	  placed	  at	  4°C	  for	  the	  same	  time	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period.	   Following	   incubation,	   cells	  were	  washed	  once	  with	   cold	   serum-­‐free	   RPMI	  medium	  
(4°C)	   followed	  by	   a	  wash	  with	   cold	   PBS	   (4°C).	   Samples	  were	   then	   fixed	  by	   the	   addition	  of	  
600µl	   of	   cold	   fixing	   solution	   (0.5%	   (v/v)	   formaldehyde	   in	   PBS,	   at	   4°C)	   and	   immediately	  
processed	  using	  flow	  cytometry.	  	  
	  
	  
Chick	  chorioallantoic	  membrane	  (CAM)	  assay	  	  
The	  angiogenic	  capacity	  of	  the	  AM	  was	  assessed	  using	  the	  chick	  chorioallantoic	  membrane	  
(CAM)	   assay.	   Briefly,	   the	   assay	   was	   performed	   on	   fertilised	   4-­‐day-­‐old	  eggs	   (Henry	   Stuart,	  
Fakenham,	  UK)	  by	  the	  direct	  addition	  of	  a	  0.5cm2	  AM	  sample	  onto	  the	  chorion.	  	  Following	  a	  
further	   6-­‐day	   incubation	   at	   37°C,	   the	   eggs	   were	   chilled	   at	   11°C	   for	   1	   hour	   and	   then	   the	  
localised	  area	  surrounding	  the	  AM/chorion	  viewed	  using	  a	  Leica	  MZ16F	  light	  microscope	  and	  
images	  captured	  using	  the	  in-­‐built	  camera	  and	  Q-­‐Capture	  software.	  Quantification	  of	  vessels	  
was	  achieved	  by	  visual	  manual	  counting	  of	  the	  number	  secondary	  vessel	  formation	  per	  mm2	  




Mean	  values	  and	  standard	  deviations	  were	  calculated	  from	  each	  sample	  and	  the	  differences	  
between	  the	  means	  were	  compared	  using	  the	  Student	  t-­‐test	  (two-­‐tailed)	  or	  one-­‐way	  ANOVA	  




Mechanical	  characteristics	  of	  TG-­‐treated	  AM	  
Native	   amniotic	   membrane	   samples	   treated	   with	   enzymatically-­‐active	   transglutaminase	  
(quantified	  using	  the	  hydroxamate	  activity	  assay)	   in	  order	  to	  catalyse	  the	  formation	  of	  ε(γ-­‐
glutamyl)lysine	   cross-­‐links	   were	   analysed	   by	   SEM.	   Figures	   1	   and	   2	   summarise	   the	   post-­‐
treatment	  effects	  on	  the	  AM	  following	  a	  24h	  treatment	  with	  1%	  (w/v)	  TG	  and	  1%	  (w/v)	  BSA	  
(as	  a	  protein	  control)	   in	  a	  humidified	   incubator	  at	  37°C	  and	  5%	  CO2.	  At	   the	  x200	  and	  x750	  
magnification	   levels,	   TG-­‐treated	   AM	   demonstrated	   a	   closer	   and	   denser	   association	   of	  
individual	   ECM	   fibrous	   matter	   compared	   to	   the	   untreated	   and	   BSA-­‐treated	   AM	   samples	  
which	  did	  not	  appear	  to	  differ	  themselves.	  Moreover,	  at	  the	  higher	  magnifications,	  the	  TG-­‐
treated	   AM	   exhibited	   a	   much	   smoother	   and	   uniform	   surface	   compared	   to	   the	   untreated	  
membrane	   sample:	   comparable	   for	   both	   the	   apical	   and	   epithelial	   sides	   of	   the	   AM.	  
Interestingly,	  the	  BSA-­‐treated	  membrane	  also	  displayed	  a	  relatively	  smooth	  surface	  but	  was	  
populated	  with	  a	  significant	  amount	  of	  aggregated	  globular	  (protein)	  material.	  	  
	  
Samples	   of	   each	   membrane	   were	   subjected	   to	   mechanical	   analysis	   using	   a	   Love	   wave	  
acoustic	   device.	   The	   device	   was	   loaded	   separately	   with	   each	   of	   the	   AM	   samples	   and	   the	  
resulting	   frequency	   shift	   and	   change	   in	   signal	   amplitude,	   relative	   to	   the	   unloaded	   device,	  
were	   recorded.	  The	  measured	   frequency	  shift	  and	  signal	  amplitude	  were	  expressed	  as	   the	  
change	   in	   the	   wavenumber	   and	   damping	   relative	   to	   the	   unperturbed	   wavenumber,	   and	  
substituted	   into	   Equation	   1.	   The	   real	   part	   of	   the	   shear	   modulus	   was	   then	   determined	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allowing	   a	   direct	   comparison	   of	   the	   membrane	   mechanical	   strength	   to	   be	   made.	   This	   is	  
summarised	   in	   Figure	   3.	   It	   can	   be	   seen	   that	   both	   the	   relative	   damping	   and	   change	   in	  
wavenumber	  of	  the	  TG-­‐treated	  AM	  are	  significantly	  lower	  (p<0.05	  and	  p<0.01,	  respectively)	  
than	  that	  of	  the	  untreated	  AM	  control	  sample.	  Moreover,	  TG-­‐treated	  AM	  also	  demonstrated	  
a	   significantly	   lower	   relative	   damping	   than	   that	   of	   the	   BSA-­‐treated	   AM	   sample	   (p<0.05).	  
Calculation	  of	  the	   individual	  shear	  modulus	   indicate	  that	  the	  TG-­‐treated	  AM	  appears	  to	  be	  
mechanically	   stronger/stiffer	   than	   the	   BSA-­‐treated	   membrane;	   with	   both	   protein-­‐treated	  
membranes	  being	  stronger/stiffer	  than	  the	  untreated	  control.	  	  
	  
	  
Transparency	  of	  the	  TG-­‐treated	  AM	  
The	  transparency	  characteristics	  of	  the	  AM	  samples	  were	  assessed	  using	  a	  simple	  visual	  test:	  
the	  ability	  to	  image/read	  specific	  words	  when	  the	  membranes	  were	  placed	  over	  sample	  text	  
as	   documented	   in	   Figure	   4.	   It	   can	   be	   seen	   that	   neither	   of	   the	   TG	   or	   BSA	   pre-­‐treatments	  
impaired	  the	  transparency	  of	  the	  AM	  samples.	  	  
	  
	  
Susceptibility	  to	  proteolytic	  degradation	  
The	   resistance	   to	   proteolytic	   degradation	   of	   the	   AM	   samples	   was	   assessed	   using	   a	  
concentration	   range	   of	   microbial	   collagenase	   (C.	   histolyticum).	   The	   collage	   of	   images	  
depicted	  by	  Figure	  5	  summarise	  the	  physical	  characteristics	  of	  the	  untreated,	  1%	  (w/v)	  BSA-­‐
treated	   and	   1%	   TG-­‐treated	   AM	   samples	   when	   exposed	   to	   0.2mg/ml	   of	   collagenase	   for	  
different	   time-­‐points.	   In	   addition,	   parallel	   supernatant	   samples	   were	   collected	   and	   their	  
protein	  concentration	  determined	  using	  the	  colorimetric	  based	  Bio-­‐Rad	  DC	  protein	  assay	  kit	  
and	   summarised	   in	   Figure	   6.	   Visual	   signs	   of	   degradation	   began	   to	   appear	   at	   the	   24	   hour	  
time-­‐point	  for	  the	  untreated	  AM	  sample	  but	  at	  the	  72	  hour	  time-­‐point	  for	  the	  BSA-­‐treated	  
sample.	   In	  contrast,	  the	  TG-­‐treated	  AM	  samples	  remained	  relatively	   intact	  up	  until	  the	  144	  
hour	  time-­‐point.	  This	  observation	  was	  further	  corroborated	  with	  the	  protein	  concentration	  
which	  demonstrated	  a	  consistent	  and	  significant	  lower	  protein	  reading	  (p<0.05)	  for	  the	  TG-­‐
treated	  AM	  samples	  compared	  to	  the	  BSA-­‐treated	  and	  untreated	  controls	  at	  the	  appropriate	  
time-­‐points.	   Moreover,	   this	   degradation	   profile	   was	   replicated	   at	   the	   1mg/ml	   and	  
0.002mg/ml	  collagenase	  concentrations	  [data	  not	  shown].	  
	  
	  	  
Cell	  culture	  characteristics	  of	  the	  TG-­‐treated	  AM	  
Figure	   7	   shows	   the	   short-­‐term	   (72	  hours)	   cell	   attachment	   and	   spreading	   characteristics	   of	  
both	   the	  U5637	  cell	   line	  and	  mDC	  on	  TCP,	  untreated	  AM,	  BSA-­‐treated	  and	  TG-­‐treated	  AM	  
samples	  when	   used	   as	   culture	   surfaces.	   Increased	   numbers	   of	   attached	  U5637	   cells	  were	  
found	  when	  cultured	  on	  the	  TG-­‐treated	  AM	  compared	  to	  the	  untreated	  AM	  sample	  and	  also	  
appeared	  to	  demonstrate	  an	  enhancement	  in	  its	  degree	  of	  spreading	  based	  on	  the	  extent	  of	  
the	  cytoplasmic	  halo	  surrounding	   the	  nucleus	   [spreading	  data	  not	   shown].	   In	  contrast,	   the	  
BSA-­‐treatment	   appeared	   to	   decrease	   the	   ability	   of	   the	   U5637	   cells	   to	   attach	   to	   the	  
membrane.	  No	  major	  differences	  were	  noted	  for	  mDC	  when	  cultured	  on	  the	  different	  AM-­‐
treated	  membranes.	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The	   metabolic	   activity	   of	   the	   cells	   was	   quantified	   using	   the	   MTS	   proliferation	   assay	   and	  
summarised	   in	   Figure	   8.	   It	   can	   be	   seen	   that	   cellular	   activity	   for	   both	   cell	   types	   was	  
significantly	   greater	   on	   the	   TG-­‐treated	  AM	   compared	   to	   the	   other	  membrane	   samples	   (at	  
the	   48	   hour	   time-­‐point).	   However,	   the	   difference	   in	   this	   effect	   became	   negligible	   at	   the	  
longer	  culture	  period	  (72	  hour	  time-­‐point)	  for	  both	  the	  U5637	  and	  mDC.	  
	  
	  
Angiogenic	  potential	  of	  AM	  (CAM	  assay)	  
A	  representative	  selection	  of	  images	  for	  the	  untreated,	  BSA-­‐treated	  and	  TG-­‐treated	  AM	  used	  
in	   the	   CAM	   assay	   is	   summarised	   in	   Figure	   9.	   Quantification,	   based	   on	   the	   formation	   of	  
secondary	   vessels	   per	   mm2,	   allows	   the	   comparison	   of	   the	   angiogenic	   potential	   of	   each	  
membrane	  to	  be	  made.	  Interestingly,	  none	  of	  samples	  appeared	  to	  inhibit	  angiogenesis	  due	  
to	  the	  presence	  of	  clear	  and	  defined	  blood	  vessels	  in	  all	  the	  samples.	  In	  some	  cases,	  it	  was	  
observed	   that	   the	   TG-­‐treated	   AM	   samples	   allowed	   the	   development	   of	   several	   smaller	  
(tertiary	  and	  quaternary)	  blood	  vessels	  compared	  to	  the	  other	  control	  conditions.	  
	  
	  
mDC	  phenotype	  and	  endocytic	  ability	  	  
Phenotypical	   analyses	   of	   the	   mDC	   following	   culture	   on	   the	   different	   substrates	   were	  
achieved	   using	   flow	   cytometry.	   Absolute	   MFI	   values	   of	   the	   surface	   markers	   of	   the	   mDC	  
samples	  are	  documented	   in	  Figure	  10.	   In	   summary,	   the	   results	   suggest	   that	  no	  phenotype	  
(or	  differentiation)	   changes	  occur	   following	  extended	  culture	  on	   the	  different	  AM	  samples	  
compared	   to	   the	   untreated	  AM	   control.	   Interestingly,	   small	   increases	   in	   the	   expression	  of	  
CD86,	   CD209	   and	   HLA-­‐DR	   were	   found	   to	   be	   induced	   following	   culture	   (48h)	   on	   the	   TG-­‐
treated	  AM	  sample	  compared	  to	  culture	  on	  TCP.	  Moreover,	  a	  decrease	  in	  CD206	  expression	  
also	  appeared	  to	  occur	  following	  culture	  on	  the	  AM	  samples	  compared	  to	  TCP	  at	  the	  48	  hour	  
time-­‐point.	  Analysis	  of	  the	  endocytic	  ability	  of	  the	  mDC	  was	  achieved	  using	  the	  FITC-­‐dextran	  
uptake	  assay	  and	  summarised	  in	  Figure	  11.	  Overall,	  absolute	  MFI	  values	  increased	  with	  time	  



















The	   major	   component	   of	   the	   amniotic	   membrane	   (AM)	   is	   collagen	   which	   is	   further	  
interdispersed	  with	  a	  variety	  of	  other	  ECM	  proteins	  [Sippel	  et	  al.,	  2001].	  Although	  this	  matrix	  
composition	   renders	   the	   AM	   insoluble	   in	   physiological	   (body	  water)	   pH,	   native	   AM	   is	   still	  
subject	  to	  quick	  in	  vivo	  degradation	  due	  to	  its	  susceptibility	  to	  proteolytic	  attack	  and	  thermal	  
instability	   [Fujisato	  et	  al.,	   1999].	  Moreover,	   further	  exploitation	  of	   the	  AM	   in	   regenerative	  
medicine	   is	   limited	   by	   its	   weak	   mechanical	   characteristics,	   stability	   post-­‐storage	   and	  
difficulty	   during	   manual	   handling.	   Although	   several	   methodologies,	   mainly	   targeting	   the	  
cross-­‐linking	  of	  collagens,	  have	  been	  employed	  to	  improve	  the	  mechanical	  properties	  of	  AM,	  
they	   are	   susceptible	   to	   leaving	   residual	   catalysts	   or	   by-­‐products	   that	   may	   induce	   an	  
inflammatory	  response	  [Lee	  et	  al.,	  2001;	  Matuda	  et	  al.,	  1999].	  To	  circumvent	  such	  problems,	  
in	  this	  study,	  we	  aimed	  to	  improve	  the	  mechanical	  properties	  of	  the	  AM	  by	  treating	  it	  with	  
the	  biological	  enzyme,	   transglutminase	   (TG).	  Previous	  work	   including	   those	  of	  others	  have	  
demonstrated	  that	  TG	  is	  capable	  of	  cross-­‐linking	  collagen	  and	  its	  derivates	  resulting	  in	  novel	  
biomaterials	   with	   improved	   mechanical,	   biological	   and	   biocompatibility	   characteristics	  
[Zeugolis	  et	  al.,	  2010;	  O’Halloran	  et	  al.,	  2006;	  Chau	  et	  al.,	  2005;	  McHale	  et	  al.,	  2005;	  Orban	  et	  
al.,	  2004;	  Chen	  et	  al.,	  2003].	  In	  addition,	  a	  significant	  portion	  of	  the	  other	  ECM	  proteins	  that	  
contribute	   to	   the	   AM	   structure	   are	   also	   substrates	   that	   can	   be	   involved	   in	   the	   TG	   cross-­‐
linking	   reaction	   [Griffin	   et	   al.,	   2002;	   Greenberg	   et	   al.,	   1991].	   Initial	   work	   using	   0.01-­‐10%	  
(w/v)	  TG,	  considerable	  physical	  and	  manual	  handling	  differences	  of	  the	  AM	  were	  observed	  
(data	  not	  shown)	  and	  samples	  were	  consequently	  treated	  with	  an	  optimal	  concentration	  of	  
1%	   (w/v)	   TG	  based	  on	  a	   combination	  of	   costs,	   sample	  preparation,	  physical	   and	  biological	  
characterisation.	  As	   such,	   following	   treatment	  with	   TG,	   our	   results	   suggest	   that	   a	   physical	  
modification/cross-­‐linking	  of	  the	  native	  AM	  has	  occurred.	  SEM	  imaging	  of	  the	  untreated	  AM	  
show	   the	   characteristic	   network	   of	   fibrous	   matter,	   most	   likely	   collagen,	   as	   previously	  
described	   [Wiese,	   1975].	   On	   treating	   the	   AM	   with	   TG,	   a	   tighter	   and	   denser	   association	  
between	   the	   individual	   fibres	   becomes	  more	   apparent	   and	   in	   addition,	   the	   lower	   stratum	  
appears	  more	  uniform,	  smoother	  and	  with	  a	  more	  organised	  arrangement.	  This	  observation	  
itself	  may	  be	  exploited	  as	  a	  pre-­‐	  or	  post-­‐treatment	  procedure	  for	  the	  standardisation	  of	  the	  
membrane	   before	   or	   after	   long-­‐term	   storage.	   Interestingly,	   a	   similar	   characteristic	  
“bundling”	   of	   collagen	   type	   I	   fibrils	   has	   been	   reported	   by	   Chau	   and	   colleagues	   following	  
treatment	   with	   microbial	   TG	   and	   analysed	   accordingly	   using	   AFM	   [Chau	   et	   al.	   2007].	   In	  
contrast,	   the	   BSA-­‐treated	   TG	   samples	   (which	   act	   as	   a	   protein-­‐only	   control)	   displayed	   the	  
loose	   fibrous	   network	   typical	   of	   native	   AM	   but	   also	   a	   significant	   amount	   of	   aggregated	  
globular	   material	   which	   was	   absent	   in	   the	   untreated	   membrane	   sample	   and	   likely	   to	   be	  
protein/component	   derived	   from	   the	   BSA.	   Although	   as	   described	   earlier,	   the	   AM	   is	  
composed	  of	  distinct	  tissue	  layers	  which	  contain	  range	  of	  proteins,	  the	  identification	  of	  the	  
exact	  proteins	   involved	  during	   the	  TG	   treatment	   is	  not	   required	  and	   is	   indeed	  beyond	   the	  
scope	   of	   this	   study;	   the	   ultimate	   aim	   of	   this	   study	   is	   to	   investigate	   the	   effects	   of	   the	   TG-­‐
treatment	  on	  native	  AM	  prior	  its	  medical	  application.	  
	  
Indication	   of	   change	   in	   the	   physical	   property	   of	   the	   modified	   AM	  was	   also	   suggested	   by	  
analysis	   using	   the	   Love	   wave	   surface	   acoustic	   device:	   a	   large	   shear	   storage	   modulus	  
represents	   a	   mechanical	   enhanced/stronger	   material.	   Moreover,	   a	   lower	   amplitude	  
displacement	   value	   is	   characteristic	   of	   a	   more	   robust/stiffer	   material.	   Accordingly,	   our	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results	  indicate	  that	  the	  TG-­‐treated	  AM	  exhibited	  both	  a	  greater	  shear	  storage	  modulus	  and	  
a	   lower	   amplitude	   displacement	   value	   compared	   to	   the	   untreated	   sample.	   Comparative	  
studies	  were	  previously	  reported	  with	  collagen,	  fibrin	  and	  gelatin-­‐based	  substrates	  following	  
treatment	   with	   TG	   in	   which	   their	   corresponding	   mechanical	   properties	   were	   significantly	  
enhanced	  by	   the	   cross-­‐linking	   reaction	   [Akpalo	  and	   Larreta-­‐Garde,	   2010;	  O’Halloran	  et	  al.,	  
2008	   and	   2006;	   Hu	   and	   Messersmith,	   2005;	   Broderick	   et	   al.,	   2005].	   Although	   not	   as	  
significant	  as	  the	  TG-­‐treated	  sample,	  enhancement	  of	  the	  mechanical	  properties	  of	  the	  BSA-­‐
treated	   AM	   also	   occurred.	   However,	   as	   BSA	   does	   not	   impart	   any	   cross-­‐linking	   effect,	   the	  
increase	  in	  stability	  may	  be	  attributed	  to	  an	  ‘artefact’	  of	  BSA	  coating	  on	  the	  AM	  directly	  or	  
by	   indirectly	  modulating	   the	   acoustic	   sampling/device.	   In	   addition,	   this	   enhanced	   physical	  
characteristic	   inferred	  a	   greater	   resistance	   to	  proteolytic	   attack	   as	  previously	  documented	  
for	   a	   collagen-­‐based	  biomaterial	   [Chau	  et	   al.,	   2005]	   and	  our	   results	   demonstrate	   a	   similar	  
behaviour	   when	   the	   AM	   is	   exposed	   to	   different	   concentrations	   of	   collagenase.	   Enhanced	  
resistance	  to	  degradation	  (0.02mg/ml	  collagenase)	  was	  maintained	  and	  observed	  for	  up	  to	  
144	   hours	   in	   the	   TG-­‐treated	   AM	   sample;	   a	   suitable	   timeframe	   and	   bioactivity	   for	   wound	  
healing	  and	  repair	  to	  occur.	  In	  contrast,	  native	  and	  BSA-­‐treated	  AM	  samples	  demonstrated	  
signs	  of	  enzymatic	  breakdown	  even	  at	  the	  lower	  concentration	  of	  collagenase	  (0.002mg/ml)	  
compared	   to	   a	   relatively	   intact	   TG-­‐treated	  membrane	   sample	   at	   the	   corresponding	   time-­‐
points.	   At	   the	   highest	   concentration	   of	   collagenase	   (1mg/ml)	   used	   in	   this	   study,	   a	   level	  
analogous	   to	   significant	   tissue	   remodelling	   and	   repair	   in	   the	   eye	   [Girard	   et	   al,	   1993],	   the	  
majority	   of	   the	   membranes	   suffered	   extensive	   degradation	   within	   24h	   although	   several	  
larger	  membrane	  fragments	  were	  still	  present	  in	  the	  48h	  time-­‐point	  for	  the	  TG-­‐treated	  AM	  
samples.	  In	  contrast,	  membranes	  were	  completely	  solubilised	  at	  the	  48h	  time-­‐point	  for	  both	  
the	  untreated	  and	  BSA-­‐treated	  AM	  samples.	  Interestingly,	  MMP-­‐1	  and	  MMP-­‐13	  are	  found	  in	  
the	  amniotic	   fluid	  at	  all	  stages	  of	  pregnancy	  and	  suggests	  that	  a	  close	   interaction	  between	  
the	   AM	   and	   the	   collagenases	   exists	   [Fortunato	   et	   al.,	   2004].	   As	   such,	   although	   our	   TG-­‐
treatment	   may	   initially	   alter	   the	   AM’s	   susceptibility	   to	   collagenase	   degradation,	   it	   still	  
ultimately	   allows	   the	   process	   to	   occur	  which	  may	   be	   important	   for	   developing	   a	   localised	  
wound	  healing	  patch	  (i.e.	  following	  amniocentesis).	  	  
	  
The	   most	   frequently	   exploited	   application	   of	   the	   AM	   is	   in	   ophthalmology	   as	   a	   novel	  
treatment	   for	   acute	   ocular	   surface	   diseases	   and	   has	   resulted	   in	   a	   variety	   of	   commercial	  
therapeutic	   products	   coming	   to	   the	   market	   (e.g.	   ArBlast®,	   	   AmbioDry®,	   AmnioGraft®	   and	  
ProKera®).	   However,	   an	   important	   stipulation	   of	   the	   biomaterial	   (especially	   for	   corneal	  
regeneration	  and	  repair)	  is	  that	  it	  should	  allow	  a	  degree	  of	  transparency	  to	  occur;	  in	  effect,	  
allow	   sight	   or	   vision	   [Connon	   et	   al.,	   2010;	   Nakamura	   et	   al.,	   2004	   and	   2003;	   Koizumi	   and	  
Kinoshita,	   2003].	   As	   reported	   in	   our	   investigation,	   the	   TG-­‐treated	   AM	   demonstrates	  
enhanced	  mechanical	  strength	  and	  stiffness	  without	  affecting	  its	  transparency	  compared	  to	  
the	   untreated	   membrane.	   However,	   this	   transparency	   assay	   is	   a	   subjective	   test	   and	   the	  
transmission	  of	  light	  and/or	  refractive	  index	  would	  need	  to	  be	  determined	  using	  alternative	  
established	  methodologies.	  Coincidentally,	  these	  visual	  characteristics	  would	  not	  be	  relevant	  
if	  the	  AM	  were	  to	  be	  used	  as	  a	  wound	  dressing	  or	  patch	  for	  tissue	  regeneration	  or	  repair.	  	  
	  
The	   attachment,	   spreading	   and	   proliferation	   characteristics	   of	   the	   U5637	   cells	   and	   mDC	  
were	   slightly	   enhanced	   during	   culture	   on	   the	   TG-­‐treated	   AM	   compared	   to	   the	   untreated	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membrane.	  Although	  no	  major	   increases	  were	  observed	   in	   these	  biological	   characteristics,	  
the	   results	   suggest	   that	   the	   TG	   treatment	   itself	   did	   not	   damage	   or	   cause	   any	   detrimental	  
effect	  to	  the	  native	  membrane	  which	  has	  already	  been	  established	  as	  a	  natural	  cell	  culture	  
substrate	  [Connon	  et	  al,	  2010].	  Moreover,	  the	  effect	  of	  the	  AM	  on	  cell	  differentiation	  and	  its	  
interaction	   with	   immune	   cells	   were	   assessed	   via	   culture	   with	   mDC.	   DC	   are	   specialised	  
antigen	  presenting	  cells	  which	  serve	  as	  sentinels	  of	  the	  immune	  system	  and	  play	  a	  key	  role	  
in	   the	   initiation	   of	   immune	   responses	   and	   activation	   of	   adaptive	   immune	   cells	   such	   as	   T-­‐
cells.	  DC	  are	  amongst	  the	  first	  immune	  cells	  that	  come	  in	  contact	  with	  foreign	  antigens	  and	  
constantly	  monitor/sample	  their	  microenvironment	  for	  the	  presence	  of	  such	  material	  using	  
different	  mechanisms	   including	  endocytosis.	  DC	  maturation,	  as	  evidenced	  by	  up-­‐regulation	  
of	  surface	  markers	  such	  as	  CD83,	  CD86	  and	  HLA-­‐DR,	  is	  usually	  observed	  after	  encountering	  
“danger	  signals”	  and	  could	  indicate	  immune	  activation	  [Banchereau	  et	  al.,	  2000;	  Banchereau	  
and	   Steinman,	   1998].	   Our	   results	   suggest	   that	   no	   significant	   long-­‐term	   phenotype	   or	  
functional	   changes	   occur	   for	   the	   mDC	   cultured	   on	   any	   of	   the	   AM	   samples.	   However,	  
interestingly,	  small	  increases	  in	  the	  expression	  of	  CD86,	  CD209	  and	  HLA-­‐DR	  were	  found	  to	  be	  
induced	  following	  48h	  of	  culture	  on	  the	  TG-­‐treated	  AM	  sample	  compared	  to	  culture	  on	  TCP.	  
This	   observation	  may	  be	  explained	  by	   a	  previous	   finding	  within	  our	   group	  which	   reported	  
that	   culturing	  mDC	   on	   either	   a	   fibronectin	   or	   laminin	   substrate	   enhanced	   their	   endocytic	  
ability	   and	   altered	   their	   phenotype	   [Garcia-­‐Nieto	   et	   al.,	   2010];	   clearly	   this	   may	   be	   a	  
possibility	  as	  ECM	  components	  of	   the	  ECM	   include	  both	   fibronectin	  and	   laminin	   [Sippel	  et	  
al.,	  2001].	  As	  such,	  these	  results	  suggest	  that	  induction	  of	  an	  inflammatory	  response	  may	  be	  
minimal	  (with	  no	  detrimental	  changes	  in	  the	  basic	  function	  or	  activation	  status	  of	  DC)	  when	  
the	  AM	  is	  exploited	  for	   in	  vivo	  use.	  Furthermore,	  TG	  has	  already	  been	  shown	  to	  be	  widely	  
distributed	  in	  its	  native	  form	  in	  the	  ciliary	  body,	  zonular	  fibres	  and	  blood	  vessel	  walls	  in	  the	  
eye	  [Raghunath	  et	  al.,	  1999].	  Based	  on	  the	  enhancement	  of	   the	  aforementioned	  biological	  
characteristics,	   the	   TG-­‐treated	   AM	  may	   also	   be	   considered	   as	   a	   novel	   tissue	   engineering	  
scaffold	  for	  cell	  culture	  applications.	  	  
	  
Although	   it	   is	   widely	   reported	   that	   the	   AM	   exhibits	   an	   anti-­‐angiogenic	   effect,	   the	   exact	  
mechanism	  by	  which	  this	  occurs	  has	  yet	  to	  be	  fully	  elucidated	  [Dua	  et	  al.,	  2004,	  Hao	  et	  al.,	  
2000;	  Bennett	  et	  al.,	  1980	  and	  1982].	  As	  several	  studies	  have	  also	  demonstrated	  a	  panel	  of	  
growth	   factors	   and/or	   cells	   within	   the	   AM	   that	   may	   contribute	   to	   the	   upregulation	   of	  
angiogenesis	   [Wolbank	  et	  al.,	  2009;	  Kim	  and	  Tseng,	  1995;	  Magnatii	  et	  al.,	  1989],	   it	  may	  be	  
feasible	  to	  suggest	  that	  the	  AM	  itself	  may	  solely	  dictate	  the	  pro-­‐	  or	  anti-­‐angiogenic	  response	  
when	   used	   in	   a	   clinical	   setting.	   Our	   results	   suggest	   that	   native	   AM,	   following	   long-­‐term	  
storage	  and	  extensive	  wash	  steps	  during	  preparation/manipulation,	  allows	  angiogenesis	   to	  
occur	   when	   exploited	   in	   a	   CAM	   assay.	   Interestingly,	   following	   treatment	   with	   TG,	   this	  
membrane	   still	   retains	   the	  pro-­‐angiogenic	   characteristic	   and	   in	   some	   cases	   (where	  n	   =	   5),	  
there	  even	  appeared	  to	  be	  an	  enhancement	  in	  the	  number	  and	  quality	  of	  vessels	  formed.	  A	  
negligible	   improvement/effect	   on	   angiogenesis	   was	   observed	   with	   the	   BSA-­‐treated	   AM	  
compared	  to	  the	  untreated	  AM	  sample.	  However,	  care	  must	  be	  taken	  when	  interpreting	  this	  






In	   summary,	  we	  demonstrate	   that	   treating	   native	  AM	  with	   TG	   leads	   to	   enhancement	   and	  
improvement	  in	  the	  mechanical	  properties	  of	  the	  membrane	  which	  is	  likely	  due	  to	  a	  change	  
in	   its	   physical	   structure	   and	   susceptibility	   to	   proteolytic	   degradation.	   Interestingly,	   this	  
treatment	   does	   not	   change	   the	   visual	   transparency	   of	   the	   membrane	   nor	   affect	   its	  
biological/biocompatibility	   characteristics.	   Taken	   together,	   these	   findings	   suggest	   that	   the	  
TG	  treatment	  on	  the	  AM	  may	  be	  exploited	  as	  a	  method	  to	  produce	  novel	  biomaterials	   for	  
cell	   culture	   applications	   and/or	   regenerative	   therapy	   or	   as	   a	   treatment	   to	   stabilise	   and	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Figure	   1.	   Scanning	   electron	  microscopy	   (SEM)	   images	  of	   untreated	   and	   treated	   amniotic	  
membrane	   (AM)	   samples.	  Untreated,	   1%	   (w/v)	   BSA-­‐treated	   and	   1%	   (w/v)	   TG-­‐treated	  AM	  
samples	  (24h,	  at	  37°C	  and	  5%	  CO2)	  were	  mounted	  onto	  aluminium	  stubs,	  gold	  coated	  under	  
an	   argon	   atmosphere	   before	   being	   imaged	   using	   a	   JOEL	   6060LV	   variable	   pressure	   SEM	  
operating	  at	  10kV	  accelerating	  voltage	  at	  x200,	  x750	  and	  x1500	  magnifications	  	  
	  
	  
Figure	  2.	  Scanning	  electron	  microscopy	   (SEM)	   images	  of	   selective	   sides	  of	  untreated	  and	  
treated	   amniotic	   membrane	   (AM)	   samples.	   Untreated	   and	   1%	   (w/v)	   TG-­‐treated	   AM	  
samples	  (24h,	  at	  37°C	  and	  5%	  CO2)	  were	  mounted	  onto	  aluminium	  stubs,	  gold	  coated	  under	  
an	   argon	   atmosphere	   before	   being	   imaged	   using	   a	   JOEL	   6060LV	   variable	   pressure	   SEM	  
operating	  at	  10kV	  accelerating	  voltage	  at	  x1500	  and	  x1000	  magnifications	  	  
	  
	  
Figure	  3.	  Mechanical	  characteristic	  profiles	  of	  untreated	  and	  treated	  amniotic	  membrane	  
(AM)	  samples.	  0.3cm2	  samples	  of	  untreated,	  1%	  (w/v)	  BSA-­‐treated	  and	  1%	  (w/v)	  TG-­‐treated	  
AM	  were	  assessed	  using	  a	  Love	  wave	  surface	  acoustic	  device	  operating	  at	  118MHz	  and	  6mm	  
separation	   path	   length.	   The	   induced	   damping	   relative	   to	   the	   unperturbed	   wavenumber	  
((Δα/β)),	   the	   change	   in	   wavenumber	   relative	   to	   the	   unperturbed	   wavenumber	   device	   a	  
(Δβ/β)	  and	  shear	  storage	  modulus	  were	  determined	  by	  deducting	  the	  residual	  background	  
reading	  of	  the	  unloaded	  device	  from	  the	  sample	  readings.	  Results	  are	  the	  mean	  values	  ±SD	  
from	  three	   independent	  samples	  with	  density	  taken	  as	  997.6Kg/m3.	  Statistical	  analysis	  was	  
performed	   using	   a	   Student’s	   t-­‐test	  with	   comparisons	   between	   the	   untreated	   AM	   and	   TG-­‐
treated	  AM	  samples	  and	  values	  corresponding	  to	  (p<0.05)	  represented	  with	  *.	  	  
	  
	  
Figure	  4.	  Transparency	  characteristics	  of	  untreated	  and	  treated	  amniotic	  membrane	  (AM)	  
samples.	  0.5cm2	  samples	  of	  untreated,	  1%	  (w/v)	  BSA-­‐treated	  and	  1%	  (w/v)	  TG-­‐treated	  AM	  
were	  assessed	  for	  their	  transparency	  by	  overlaying	  the	  membrane	  samples	  onto	  a	  piece	  of	  




Figure	   5.	   Susceptibility	   to	   collagenase	   degradation	   of	   untreated	   and	   treated	   amniotic	  
membrane	  (AM)	  samples.	  0.5cm2	  samples	  of	  untreated,	  1%	  (w/v)	  BSA-­‐treated	  and	  1%	  (w/v)	  
TG-­‐treated	   AM	  were	   exposed	   to	   0.2mg/ml	   of	   microbial	   collagenase	   (C.	   histolyticum)	   in	   a	  
humidified-­‐atmosphere	  incubator,	  at	  37oC	  and	  with	  5%	  CO2,	  for	  several	  selected	  time	  points.	  
Samples	   were	   then	   viewed	   using	   a	   Veho	   VMS-­‐004	   Discovery	   microscope	   and	   images	  
captured	  using	  the	  in-­‐built	  camera	  and	  Q-­‐Capture	  software	  
	  
Figure	  6.	  Supernatant	  protein	  concentration	  of	  untreated	  and	  treated	  amniotic	  membrane	  
(AM)	   samples	   following	   exposure	   to	   collagenase.	   Residual	   solubilised	   protein	   in	   the	  
 23	  
supernatants	   of	   the	   AM	   samples	   were	   assessed	   using	   the	   Bio-­‐Rad	   DC	   protein	   assay	   kit	  
following	   exposure	   to	   0.2mg/ml	   of	  microbial	   collagenase	   (C.	   histolyticum)	   in	   a	   humidified-­‐
atmosphere	  incubator,	  at	  37oC	  and	  with	  5%	  CO2,	  for	  several	  selected	  time	  points	  before	  the	  
absorbance	  was	  read	  at	  750nm	  using	  an	  Tecan	  Infinite®	  M200	  PRO	  plate	  reader.	  Results	  are	  
the	   mean	   values	   ±SD	   from	   three	   independent	   experiments	   with	   each	   having	   triplicate	  
samples.	   Statistical	   analysis	   was	   performed	   using	   a	   Student’s	   t-­‐test	   with	   comparisons	  
between	   the	   untreated	   AM	   and	   TG-­‐treated	   AM	   samples	   and	   values	   corresponding	   to	  
(p<0.05)	  represented	  with	  *,	   (p<0.01)	  represented	  with	  **	  and	  (p<0.001)	  represented	  with	  




Figure	  7.	  Attachment	  and	  spreading	  characteristics	  of	  U5637	  cells	  and	  mDC	  on	  untreated	  
and	  treated	  amniotic	  membrane	  (AM)	  samples.	  After	  72	  hours	  of	  culture	  on	  the	  substrates	  
in	  a	  humidified-­‐atmosphere	   incubator,	  at	  37oC	  and	  with	  5%	  CO2,	  cells	  were	  washed	  before	  
being	   fixed	   in	   4%	   (w/v)	   paraformaldehyde,	   permeabilised	   using	   0.1%	   (v/v)	   Triton	   X-­‐100	   in	  
PBS	   and	   stained	   with	  May-­‐Grunwald	   and	   Giemsa	   stains.	   Samples	   were	   then	   viewed	   with	  
Nikon	   SM21500	   microscope	   (x20	   magnification)	   and	   images	   captured	   using	   the	   in-­‐built	  
Nikon	  Digital	  DS-­‐L1	  image	  capture	  unit.	  TCP	  =	  tissue	  culture	  plastic	  
	  
	  
Figure	   8.	   Metabolic	   activity	   characteristics	   of	   U5637	   cells	   and	   mDC	   on	   untreated	   and	  
treated	  amniotic	  membrane	  (AM)	  samples.	   (A)	  U5637	  cells	  and	  (B)	  mDC	  were	  cultured	  on	  
the	  substrates	  in	  a	  humidified-­‐atmosphere	  incubator,	  at	  37oC	  and	  with	  5%	  CO2,	  cells	  for	  the	  
appropriate	   time	   points	   before	   metabolic	   activity	   was	   determined	   using	   the	   CellTiter	   AQ	  
solution	   according	   to	   the	   manufacturer’s	   instructions.	   Sample	   absorbances	   were	   read	   at	  
492nm	  using	  an	  Optima	  FLUOstar®	  plate	  reader.	  Results	  are	  the	  mean	  values	  ±SD	  from	  three	  
independent	   experiments	   with	   each	   having	   triplicate	   samples.	   Statistical	   analysis	   was	  
performed	   using	   a	   Student’s	   t-­‐test	  with	   comparisons	   between	   the	   untreated	   AM	   and	   TG-­‐
treated	  AM	  samples	  and	  values	  corresponding	  to	  (p<0.05)	  represented	  with	  *.	  Comparisons	  
between	   the	   BSA-­‐treated	   AM	   and	   TG-­‐treated	   AM	   samples	   with	   values	   corresponding	   to	  
(p<0.05)	   are	   represented	  with	   +.	  AM	  =	  untreated	  AM,	  BAM	  =	  BSA-­‐treated	  AM,	  TAM	  =	  TG-­‐
treated	  AM,	  TCP	  =	  tissue	  culture	  plastic	  
	  
	  
Figure	   9.	   Angiogenic	   potential	   of	   the	   untreated	   and	   treated	   amniotic	   membrane	   (AM)	  
samples.	   The	   angiogenic	   potential	   of	   the	   AM	   samples	   was	   determined	   using	   the	   chick	  
chorioallantoic	  membrane	   (CAM)	   assay.	   0.5cm2	  AM	   samples	  were	   initially	   placed	   onto	   the	  
chorion	  of	  a	  4	  day	  old	  egg	  and	  then,	  following	  6	  days	  of	  incubation	  at	  37°C,	  the	  AM/chorion	  
was	  viewed	  using	  a	  Leica	  MZ16F	  light	  microscope	  (x40	  magnification)	  and	  images	  captured	  
using	   the	   in-­‐built	   camera	   and	   Q-­‐Capture	   software.	   Images	   are	   a	   representative	   of	   5	  




Figure	  10.	  Phenotype	  of	  mDC	  cultured	  on	  untreated	  and	  treated	  amniotic	  membrane	  (AM)	  
samples.	  Summary	  of	  absolute	  MFI	  expression	  for	  mDC	  surface	  markers	  when	  cultured	  on	  
the	   different	   substrates	   at	   the	   48h	   time-­‐point.	   [absolute	   MFI	   =	   (MFI	   of	   sample)	   –	   (MFI	  
isotype/unstained)].	   Samples	   were	   analysed	   using	   a	   Beckman	   Coulter	   EPICS	   Altra	   flow	  




Figure	   11.	   Endocytic	   characteristics	   of	  mDC	   cultured	   on	   untreated	   and	   treated	   amniotic	  
membrane	  (AM)	  samples.	  Summary	  of	  absolute	  MFI	  expression	  for	  FITC-­‐dextran	  uptake	  of	  
mDC	  when	  cultured	  on	  the	  different	  substrates	  at	  the	  48h	  time-­‐point.	  [absolute	  MFI	  =	  (MFI	  
of	   sample)	   –	   (MFI	   isotype/unstained)].	   A	   4°C	   control	   sample	   was	   also	   included	   in	   the	  
corresponding	  MFI	  calculations.	  Samples	  were	  analysed	  using	  a	  Beckman	  Coulter	  EPICS	  Altra	  
flow	   cytometer	   with	   8000	   events	   sampled	   per	   condition.	   Values	   represent	   average	   value	  
from	  n=2	  experiments	  
	  
	  
